Humacyte reports Q3 2022 net loss $25.3M, cash $171.7M, BLA filing for vascular trauma mid 2023

Humacyte, Inc.

2022-Q3 EPS reported -$0.08

Cash $171.7M at Sep 30, 2022; net loss $25.3M for Q3; cash runway through 2024.
BLA filing for HAV in vascular trauma anticipated mid 2023; 56 patients enrolled in V005 trial as of Oct 31.
Phase 3 AV access trial nearing completion (227 of 240 enrolled); top-line results 1 yr after enrollment.
Appointed Dr. Cindy Cao as Chief Regulatory Officer and Lt. Gen. C. Bruce Green to Board.
Partnered with Diabetes Research Institute for Biovascular Pancreas program in type 1 diabetes.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Humacyte, Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 10, 2022, Humacyte, Inc. issued a press release regarding its financial results for its fiscal third quarter ended September 30, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Humacyte, Inc. filing history →

Source: SEC EDGAR

accession 0001818382-22-000179

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.